321 related articles for article (PubMed ID: 24261583)
1. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
Dingemanse J; Sidharta PN; Maddrey WC; Rubin LJ; Mickail H
Expert Opin Drug Saf; 2014 Mar; 13(3):391-405. PubMed ID: 24261583
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Sidharta PN; Krähenbühl S; Dingemanse J
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
[TBL] [Abstract][Full Text] [Related]
3. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis.
Raja SG
Curr Opin Investig Drugs; 2010 Sep; 11(9):1066-73. PubMed ID: 20730702
[TBL] [Abstract][Full Text] [Related]
4. Macitentan for the treatment of pulmonary arterial hypertension.
DuBrock HM; Channick RN
Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
[TBL] [Abstract][Full Text] [Related]
5. Macitentan for the treatment of pulmonary arterial hypertension.
Kholdani CA; Fares WH; Trow TK
Vasc Health Risk Manag; 2014; 10():665-73. PubMed ID: 25473292
[TBL] [Abstract][Full Text] [Related]
6. Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Pulido T; Adzerikho I; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Jing ZC; Le Brun FO; Mehta S; Mittelholzer CM; Perchenet L; Sastry BK; Sitbon O; Souza R; Torbicki A; Zeng X; Rubin LJ; Simonneau G;
N Engl J Med; 2013 Aug; 369(9):809-18. PubMed ID: 23984728
[TBL] [Abstract][Full Text] [Related]
7. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
[TBL] [Abstract][Full Text] [Related]
8. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
Belge C; Delcroix M
Ther Adv Respir Dis; 2019; 13():1753466618823440. PubMed ID: 30736726
[TBL] [Abstract][Full Text] [Related]
9. Macitentan for the treatment of pulmonary arterial hypertension.
Sood N
Expert Opin Pharmacother; 2014 Dec; 15(18):2733-9. PubMed ID: 25385427
[TBL] [Abstract][Full Text] [Related]
10. Macitentan for the treatment of pulmonary arterial hypertension.
Spikes L; Williamson T; Satterwhite L
Drugs Today (Barc); 2014 Jun; 50(6):401-6. PubMed ID: 24983588
[TBL] [Abstract][Full Text] [Related]
11. Development of macitentan for the treatment of pulmonary arterial hypertension.
Selej M; Romero AJ; Channick RN; Clozel M
Ann N Y Acad Sci; 2015 Nov; 1358():68-81. PubMed ID: 26291180
[TBL] [Abstract][Full Text] [Related]
12. Macitentan for the treatment of pulmonary arterial hypertension.
Hong IS; Coe HV; Catanzaro LM
Ann Pharmacother; 2014 Apr; 48(4):538-47. PubMed ID: 24458948
[TBL] [Abstract][Full Text] [Related]
13. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
Gatfield J; Mueller Grandjean C; Sasse T; Clozel M; Nayler O
PLoS One; 2012; 7(10):e47662. PubMed ID: 23077657
[TBL] [Abstract][Full Text] [Related]
14. Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension.
Clarke M; Walter C; Agarwal R; Kanwar M; Benza RL
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):415-21. PubMed ID: 24851934
[TBL] [Abstract][Full Text] [Related]
15. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
Iglarz M; Bossu A; Wanner D; Bortolamiol C; Rey M; Hess P; Clozel M
Life Sci; 2014 Nov; 118(2):333-9. PubMed ID: 24582812
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
Sidharta PN; van Giersbergen PL; Dingemanse J
J Clin Pharmacol; 2013 Nov; 53(11):1131-8. PubMed ID: 23900878
[TBL] [Abstract][Full Text] [Related]
17. Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension.
Monaco TJ; Davila CD
Drug Des Devel Ther; 2016; 10():1675-82. PubMed ID: 27274200
[TBL] [Abstract][Full Text] [Related]
18. Macitentan: a review of its use in patients with pulmonary arterial hypertension.
Dhillon S
Drugs; 2014 Sep; 74(13):1495-507. PubMed ID: 25060980
[TBL] [Abstract][Full Text] [Related]
19. [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension].
Avdeev SN
Ter Arkh; 2016; 88(7):89-97. PubMed ID: 27459621
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.
Iglarz M; Binkert C; Morrison K; Fischli W; Gatfield J; Treiber A; Weller T; Bolli MH; Boss C; Buchmann S; Capeleto B; Hess P; Qiu C; Clozel M
J Pharmacol Exp Ther; 2008 Dec; 327(3):736-45. PubMed ID: 18780830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]